Skip to Content
Merck
  • [Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp].

[Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp].

Medicina clinica (2012-10-30)
Juan José Castón, María José Linares, Antonio Rivero, Manuel Casal, Julián Torre-Cisneros
ABSTRACT

To determine clinical variables to distinguish invasive pulmonary aspergillosis (IPA) from colonization in patients with chronic pneumopathies with positive culture of Aspergillus spp. in respiratory samples. Retrospective cohort study including patients with respiratory isolations of Aspergillus spp. during a period of 10 years. IPA was evaluated according to the Bulpa criteria. Clinical variables were collected and a multiple logistic regression analysis was carried out. Eighty-three patients with isolation of Aspergillus spp. from respiratory samples were included; 68.7% (n=57) of the patients had chronic obstructive pulmonary disease, 18% (n=15) pulmonary fibrosis and 13.3% (n=11) bronchial asthma. Twenty-two patients (26.6%) had IPA. The use of fluconazole (OR 4.49; CI 95% 1.5-13.4; P=.007), severe respiratory failure (OR 4.64; CI 95% 1.46-14.72; P=.009) and hospitalization time (OR 1.05; CI 95% 1.01-1.1; P=.006) were associated with IPA. Prior use of fluconazole, severe respiratory failure and hospitalization time are associated with IPA in patients with chronic pneumopathies with respiratory isolation of Aspergillus spp.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nystatin Suspension, suspension, 10,000 unit/mL in DPBS, BioReagent, suitable for cell culture
Sigma-Aldrich
Nystatin, powder, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Nystatin, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Nystatin, ≥4,400 USP units/mg
Nystatin, European Pharmacopoeia (EP) Reference Standard